Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Lynozyfic, a therapy for recurrent multiple myeloma, boosting the company's shares by 2%.

Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.

BWX Technologies, Inc. (NYSE:BWXT) is one of the top 10 nuclear energy stocks to invest in for the next decade. On June 5, ...